Cinzia Ciccacci1, Andrea Latini2, Cristina Politi2, Sandro Mancinelli3, Maria C Marazzi4, Giuseppe Novelli2, Leonardo Palombi3, Paola Borgiani2. 1. Department of Biomedicine and Prevention, Genetics Section, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy. cinziaciccacci@libero.it. 2. Department of Biomedicine and Prevention, Genetics Section, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy. 3. Department of Biomedicine and Prevention, Epidemiology Section, University of Rome Tor Vergata, 00133, Rome, Italy. 4. Department of Human Sciences, LUMSA University, 00193, Rome, Italy.
Abstract
PURPOSE: Nevirapine (NVP) is used in developing countries as first-line treatment of HIV infection. Unfortunately, its use is associated with common serious adverse drug reactions, such as liver toxicity and the most severe and rare Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). GSTT1 and GSTM1 genes code for enzymes involved in the metabolism of a wide range of drugs. We hypothesized that this gene variability could be implicated in NVP adverse reactions. METHODS: We analyzed the GSTM1 and GSTT1 null genotypes by multiplex PCR in a population of 181 patients from Mozambique, treated with NVP. A case/control association study was performed. We also counted the number of risk alleles in SJS/TEN patients and in controls, including the GSTM1 null genotype and four previously identified risk alleles in CYP2B6, HCP5, and TRAF3IP2 genes. RESULTS: Among patients, 27 had developed SJS/TEN and 76 had developed hepatotoxicity during the treatment. The GSTM1 null genotype was more frequent in the cases with SJS/TEN than in the controls (OR = 2.94, P = 0.027). This association is also observed when other risk factors are taken into account, by a multivariate analysis (P = 0.024 and OR = 3.58). The risk allele counting analysis revealed a significantly higher risk for SJS/TEN in patients carrying three or four risk alleles. Moreover, all subjects with five or six risk alleles developed SJS/TEN, while subjects without any risk alleles were present only in the control group. CONCLUSIONS: We observed an association between GSTM1 and SJS/TEN susceptibility. Moreover, GSTM1 contributes to the definition of a genetic risk profile for SJS/TEN susceptibility.
PURPOSE: Nevirapine (NVP) is used in developing countries as first-line treatment of HIV infection. Unfortunately, its use is associated with common serious adverse drug reactions, such as liver toxicity and the most severe and rare Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). GSTT1 and GSTM1 genes code for enzymes involved in the metabolism of a wide range of drugs. We hypothesized that this gene variability could be implicated in NVP adverse reactions. METHODS: We analyzed the GSTM1 and GSTT1 null genotypes by multiplex PCR in a population of 181 patients from Mozambique, treated with NVP. A case/control association study was performed. We also counted the number of risk alleles in SJS/TEN patients and in controls, including the GSTM1 null genotype and four previously identified risk alleles in CYP2B6, HCP5, and TRAF3IP2 genes. RESULTS: Among patients, 27 had developed SJS/TEN and 76 had developed hepatotoxicity during the treatment. The GSTM1 null genotype was more frequent in the cases with SJS/TEN than in the controls (OR = 2.94, P = 0.027). This association is also observed when other risk factors are taken into account, by a multivariate analysis (P = 0.024 and OR = 3.58). The risk allele counting analysis revealed a significantly higher risk for SJS/TEN in patients carrying three or four risk alleles. Moreover, all subjects with five or six risk alleles developed SJS/TEN, while subjects without any risk alleles were present only in the control group. CONCLUSIONS: We observed an association between GSTM1 and SJS/TEN susceptibility. Moreover, GSTM1 contributes to the definition of a genetic risk profile for SJS/TEN susceptibility.
Authors: M C Marazzi; P Germano; G Liotta; G Guidotti; S Loureiro; A da Cruz Gomes; M C Valls Blazquez; P Narciso; C F Perno; S Mancinelli; L Palombi Journal: HIV Med Date: 2006-07 Impact factor: 3.180
Authors: M Tohkin; N Kaniwa; Y Saito; E Sugiyama; K Kurose; J Nishikawa; R Hasegawa; M Aihara; K Matsunaga; M Abe; H Furuya; Y Takahashi; H Ikeda; M Muramatsu; M Ueta; C Sotozono; S Kinoshita; Z Ikezawa Journal: Pharmacogenomics J Date: 2011-09-13 Impact factor: 3.550
Authors: Collet Dandara; Jane Sayi; Collen M Masimirembwa; Ayoub Magimba; Sylvia Kaaya; Kierk De Sommers; Jacques René Snyman; Julia A Hasler Journal: Clin Chem Lab Med Date: 2002-09 Impact factor: 3.694
Authors: Dora Janeth Fonseca; Adrien Morel; Kevin Llinás-Caballero; David Bolívar-Salazar; Paul Laissue Journal: Pharmgenomics Pers Med Date: 2021-03-01
Authors: E C Kuijper; L E French; C P Tensen; M H Vermeer; J N Bouwes Bavinck Journal: J Eur Acad Dermatol Venereol Date: 2020-05-15 Impact factor: 6.166